A Review on Chronotherapeutic Pulsatile Drug Delivery Systems in Diabetes Mellitus

Review Article

Abstract

Diabetes mellitus is a global metabolic crisis characterized by chronic hyperglycemia, where progressive pancreatic -cell dysfunction and peripheral insulin resistance lead to systemic microvascular and macrovascular complications. Although diverse classes of oral and injectable antidiabetic agents exist, conventional static dosing regimens frequently fail to achieve tight glycemic control due to their inability to synchronize with the highly dynamic circadian fluctuations of metabolic physiology. Endogenous insulin secretion, hepatic gluconeogenesis, peripheral glucose uptake, and counter-regulatory hormone actions are tightly governed by the suprachiasmatic nucleus and autonomous peripheral molecular clocks. These circadian oscillations generate predictable temporal patterns of hyperglycemia, such as the early morning dawn phenomenon, nocturnal glycemic instability, and meal-associated postprandial glucose surges. Chronotherapy via pulsatile drug delivery systems offers a sophisticated therapeutic approach by releasing active pharmaceutical ingredients after predetermined lag phases or in direct response to physiological biomarkers. Integrating these systems with smart, glucose-responsive biomaterials, polymeric nanoformulations, and microneedle platforms allows for the biomimetic restoration of physiological insulin profiles and timed delivery of oral secretagogues. Despite technical hurdles regarding batch-to-batch reproducibility, long-term biocompatibility, and complex regulatory approval rules for combination drug-device systems, these responsive technologies represent a critical step toward automated, personalized metabolic management. Aligning therapeutic delivery with the patient's endogenous circadian biology provides a viable pathway to optimize pharmacodynamic outcomes, mitigate nocturnal hypoglycemic crises, and limit cumulative organ damage